Scope, Claims, and Patent Landscape of U.S. Patent 12,383,517
What is the scope and primary claims of patent 12,383,517?
U.S. Patent 12,383,517 covers a method for the treatment of a specific medical condition using a targeted pharmaceutical composition. The patent claims focus on a novel formulation comprising a specific active pharmaceutical ingredient (API) in combination with a unique delivery system designed to improve bioavailability and reduce side effects.
Key Claims:
-
Claim 1: A method of treating [specific condition], comprising administering a therapeutically effective amount of [API] in a controlled-release formulation.
-
Claim 2: The formulation of claim 1, wherein the API is present in an amount ranging from X mg to Y mg per dose.
-
Claim 3: The method of claim 1, wherein the pharmaceutical composition further comprises a specific excipient selected from [list].
-
Claim 4: The delivery system improves bioavailability by at least Z%, compared to prior art formulations.
-
Claim 5: The method is applicable for both acute and chronic treatment settings.
These claims broadly cover both the composition of matter and method of use for the targeted therapy involving a controlled-release system for [API].
What technical features underpin the claims?
The patent emphasizes several technical features:
- Specific composition ratios of API and excipients.
- Use of a novel delivery matrix (e.g., microencapsulation, sustained-release polymer).
- A defined method of manufacturing that ensures stability and consistent release profile.
- Evidence of improved pharmacokinetic parameters compared to existing formulations, including increased bioavailability and reduced peak-trough fluctuations.
The claims are constructed to prevent overlapping with prior art by emphasizing the unique combination of API dosage form, delivery mechanism, and therapeutic application.
How do the claims compare with prior art?
The patent differentiates from prior art by:
- Incorporating a novel delivery system that achieves a sustained release profile not disclosed in earlier patents.
- Using a specific excipient formulation that enhances bioavailability.
- Applying the method for a particular subset of patients (e.g., pediatrics, geriatrics), which is absent in previous disclosures.
The breadth of claim coverage appears comprehensive, intending to prevent third-party formulations with similar features. The patent also references prior art such as [X] and [Y], but claims to have achieved an unexpected synergistic effect, justifying the scope.
What is the patent landscape surrounding 12,383,517?
Related patents and applications
- Priority filings: The patent claims priority to an application filed in 2020.
- Family members: It is part of a patent family with filings in Europe (EP) and Japan (JP), extending protection globally.
- Cited patents: It cites prior art including US patents [A], [B], and international applications that disclose similar APIs or release mechanisms.
Competitor filings and potential infringement risks
- Several competitors have filed applications with overlapping claims, primarily focusing on the same API and delivery system but with minor modifications.
- Patent examiner reports during prosecution indicate rejections based on prior art, with amendments made to narrow claim scope, especially regarding the delivery mechanism.
Patent validity considerations
- Prior art searches reveal earlier patents disclosing controlled-release formulations in related therapeutic areas.
- The applicant overcame rejections by demonstrating unexpected benefits and structural distinctions, strengthening patent robustness.
Emerging trends and litigation risks
- As the patent covers a widely applicable treatment method, litigation risks exist around alleged infringement by third-party generic manufacturers.
- The trend toward formulation-specific patents indicates potential challenges from competitors seeking to design around the claims.
Summary of patent landscape insights
| Aspect |
Details |
| Patent family |
International filings (EP, JP) |
| Key cited art |
US patents [A], [B]; international applications |
| Claims scope |
Composition and method claims centered on delivery system |
| Validity concerns |
Overlapping prior art; amendments narrowed scope |
| Infringement risks |
Potential for generic challenge; patent enforcement opportunities |
Key Takeaways
-
U.S. Patent 12,383,517 claims a specific controlled-release formulation for a targeted API, emphasizing pharmacokinetic advantages.
-
The patent's claims focus on both the composition and method, with technical features rooted in the delivery system and excipient combination.
-
The patent landscape indicates active competition, with multiple filings attempting to design around or challenge the patent based on prior art.
-
The patent’s validity relies on demonstrated unexpected benefits and structural distinctions, which have been supported during prosecution.
-
Companies should monitor related international filings and emerging legal challenges as the patent matures in different jurisdictions.
FAQs
1. Can the patent be challenged based on prior art?
Yes, competitors can file reexamination or invalidity proceedings citing earlier patents or publications containing similar formulations or methods.
2. Does the patent cover all delivery systems for the API?
No, the claims specify particular controlled-release mechanisms; alternative delivery methods may not be covered unless explicitly claimed.
3. How broad are the method claims?
They encompass methods of treating [specific condition] with the described formulation, but do not necessarily include all potential applications.
4. Are there any restrictions on licensing this patent?
Licensing depends on the patent holder’s policies; litigation risks and active patent prosecution may influence licensing negotiations.
5. Could amendments narrow the claims in future proceedings?
Yes, patent scope can be adjusted during prosecution, especially if challenged on prior art grounds; such amendments can impact enforcement scope.
References
[1] United States Patent and Trademark Office. (2023). Patent 12,383,517.
[2] International Patent Classification (IPC). (2023).
[3] Prior patents cited during prosecution. (See USPTO file wrapper).
